Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure (Beyond-MyoHF)

Aristotle University Of Thessaloniki

Status: Enrolling

Conditions: Valvular Heart Disease; Biochemical Dysfunction; Cardiovascular Diseases; Heart Failure

Treatments: Diagnostic Test: Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers

Study type: Observational

Funder types: Other

Identifiers

NCT05573997

19/2022

Details and patient eligibility

About

This study seeks to investigate the clinical value of novel echocardiographic indices, including myocardial work parameters, during the acute phase of heart failure hospitalization. The trajectory of novel echocardiographic indices from the start to the end of hospitalization will be captured, as a means to unravel and subsequently better understand the diverse pathophysiology of different phenotypes of the heart failure continuum. Correlation between novel echocardiographic indices with clinical data, biochemical data, different heart failure phenotypes, and therapeutic maneuvers will be attempted. Prognostic implications of those indices will be explored.

Full description

Despite ongoing advances in early diagnosis and therapy, heart failure (HF) represents a worldwide health burden with high in-hospital mortality during the acute phase of hospitalization and high readmission rates following the event of decompensation. Patients acutely hospitalized for HF represent a widely heterogenous population in terms of primary etiology, clinical manifestations, echocardiographic characteristics, appropriate therapeutic management, and prognosis.

As more advanced HF therapeutic strategies are emerging, the cardiology community attempts to identify new HF sub-phenotypes that will serve as successful recipients of such treatments. The role of echocardiography in this attempt is far from exhausted, as novel indices are entering the research arena potentially capable of identifying new phenotypes, enlightening the subtending pathophysiology, and providing incremental prognostic information.

All adult patients acutely admitted at the Department of Cardiology at AHEPA University General Hospital of Thessaloniki with symptoms and/or signs of HF meeting the inclusion criteria will be invited to participate in the present study. A complete and comprehensive medical interview will be conducted in each eligible patient. Demographic characteristics and baseline medical history, including primary etiology and clinical presentation of hospitalization will be recorded for all participants. Pharmacological and non-pharmacological standard of care therapeutic maneuvers during the acute phase of hospitalization, as well as medical therapy upon admission and discharge will be collected. A comprehensive transthoracic echocardiographic assessment (TTE) including 2-dimensional-speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work of the left and right ventricle will be performed during hospitalization. The first TTE will be performed within 24 hours from admission, and the second within 24 hours pre-discharge, to capture the trajectory and net variations of all echocardiographic indices of interest. Blood samples for biochemical analysis, including N-terminal pro-B-type natriuretic peptide plasma concentrations will be collected upon admission and prior to discharge.

Through this prospective registry, association of novel echocardiographic indices and their net changes during hospitalization with clinical and biochemical data, diverse HF phenotypes, therapeutic maneuvers, and response to treatment will be attempted, as a means to explore the pathophysiology of different HF phenotypes and ultimately provide individualized acute HF management guidance. The clinical value and prognostic implications of those echocardiographic indices will be investigated during follow-up.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients acutely admitted at the Department of Cardiology of AHEPA University General Hospital, Thessaloniki, Greece with symptoms and/or signs of heart failure (HF), as those are defined by the European Society of Cardiology.
2. Patients with abnormal plasma concentration of N-terminal pro-B-type natriuretic peptide, measured within 24 hours from admission
3. Objective echocardiographic evidence of cardiac structural and/or functional abnormalities consistent with the presence of left ventricular (LV) systolic dysfunction/diastolic dysfunction/raised LV filling pressures upon admission assessment

Exclusion criteria

1. Symptoms and/or signs of HF secondary to congenital heart disease, infective endocarditis, pericardial disease, and history of recent cardiac surgery (<1 month)
2. Patients receiving maintenance hemodialysis
3. Patients with active malignancy and/or life expectancy < 1 year
4. Poor echocardiographic acoustic windows precluding reliable assessment and/or analysis
5. Heart transplantation
6. Patients not providing informed written consent to participate in the study

Trial design

300 participants in 3 patient groups

Heart failure with reduced ejection fraction

Description:

Left Ventricular Ejection Fraction of ≤40%

Treatment:

Diagnostic Test: Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers

Heart failure with mid-range ejection fraction

Description:

Left Ventricular Ejection Fraction of 41-49%

Treatment:

Diagnostic Test: Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers

Heart failure with preserved ejection fraction

Description:

Left Ventricular Ejection Fraction of ≥50%

Treatment:

Diagnostic Test: Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers